Showing results (1-10 of 53) with videos related to
Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Interaction of Cisplatin with the human organic cation transporter 2Kelly K Filipski, Walter J Loos, Jaap Verweij, et al.Clinical Pharmacokinetics|July 8, 2003
Pharmacological effects of formulation vehicles : implications for cancer chemotherapyAlbert J ten Tije, Jaap Verweij, Walter J Loos, et al.The Oncologist|December 7, 2007
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomasMetin Tascilar, Walter J Loos, Caroline Seynaeve, et al.Current Cancer Drug Targets|August 22, 2002
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecanRon H J Mathijssen, Walter J Loos, Jaap Verweij, et al.Cancer Biology & Therapy|May 27, 2005
Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r)Charity D Scripture, Janos Szebeni, Walter J Loos, et al.Clinical Pharmacology and Therapeutics|October 10, 2003
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteinsWalter J Loos, Sharyn D Baker, Jaap Verweij, et al.Current Clinical Pharmacology|August 1, 2008
The relevance of microdialysis for clinical on:cologyJos J E M Kitzen, Jaap Verweij, Erik A C Wiemer, et al.Journal of the National Cancer Institute|August 22, 2002
Effects of St. John's wort on irinotecan metabolismRon H J Mathijssen, Jaap Verweij, Peter de Bruijn, et al.Anti-Cancer Drugs|December 1, 2005
Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion methodFrederike K Engels, Dirk Buijs, Walter J Loos, et al.Cancer Biology & Therapy|June 16, 2006
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxelFrederike K Engels, Ron A A Mathot, Walter J Loos, et al.Pageof 6